Bioextrax AB (publ) (BIOEX.ST)
Lund, SE
Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.12% | +8.75% | +1.56% | -14.43% | +26.70% | +11.54% | -14.71% | -64.25% | -96.57% | -29.27% | -29.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Waste Management: +4.3%+47.0% ★ Q1'26: +134.2% (vs Q1'25)
-
EPS growth Waste Management: +10.8%+13.5% ★ Q1'26: +5.9% (vs Q1'25)
-
FCF margin FCF growth · Waste Management: +46.5%-3,548.5% Q1'26: -8,955.7% (vs Q1'25)
-
EBIT margin Waste Management: +13.2%-2,426.4% Q1'26: -2,362.2% (vs Q1'25)
-
ROIC Waste Management: +6.2%-106.3% Q1'26: -328.3% (vs Q1'25)
-
Share dilution Waste Management: +0.0%+18.9% Q1'26: +17.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Waste Management: 1.12×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.06M
est: 1.02M (+101.6%)
|
515.0K
est: 2.13M (-75.9%)
|
757.0K
est: 1.05M (-28.2%)
|
2.34M
2.34M – 2.34M
+121.6% YoY
|
6.08M
6.08M – 6.08M
+160.4% YoY
|
28.92M
28.92M – 28.92M
+375.6% YoY
|
56.78M
56.78M – 56.78M
+96.3% YoY
|
77.83M
77.83M – 77.83M
+37.1% YoY
|
| EBITDA |
-20.65M
est: -1.02M (-1,924.1%)
|
-16.18M
est: -2.13M (-658.1%)
|
-17.24M
est: -1.05M (-1,535.9%)
|
-2.34M
-2.34M – -2.34M
-121.6% YoY
|
-6.08M
-6.08M – -6.08M
-160.4% YoY
|
-28.92M
-28.92M – -28.92M
-375.6% YoY
|
-56.78M
-56.78M – -56.78M
-96.3% YoY
|
-77.83M
-77.83M – -77.83M
-37.1% YoY
|
| EBIT |
-21.51M
est: -1.02M (-2,008.5%)
|
-17.34M
est: -2.13M (-712.4%)
|
-18.37M
est: -1.05M (-1,642.7%)
|
-2.34M
-2.34M – -2.34M
-121.6% YoY
|
-6.08M
-6.08M – -6.08M
-160.4% YoY
|
-28.92M
-28.92M – -28.92M
-375.6% YoY
|
-56.78M
-56.78M – -56.78M
-96.3% YoY
|
-77.83M
-77.83M – -77.83M
-37.1% YoY
|
| Net Income |
-21.51M
est: -24.00M (+10.4%)
|
-17.34M
est: -27.35M (+36.6%)
|
-17.71M
est: -8.32M (-112.8%)
|
-14.66M
-14.66M – -14.66M
-76.2% YoY
|
-10.70M
-10.70M – -10.70M
+27.0% YoY
|
3.17M
3.17M – 3.17M
+129.6% YoY
|
19.81M
19.81M – 19.81M
+525.0% YoY
|
31.69M
31.69M – 31.69M
+60.0% YoY
|
| SGA |
—
est: 16.33M (-100.0%)
|
1.80M
est: 8.87M (-79.7%)
|
—
est: 4.38M (-100.0%)
|
9.71M
9.71M – 9.71M
+121.6% YoY
|
25.29M
25.29M – 25.29M
+160.4% YoY
|
120.26M
120.26M – 120.26M
+375.6% YoY
|
236.08M
236.08M – 236.08M
+96.3% YoY
|
323.60M
323.60M – 323.60M
+37.1% YoY
|
| EPS |
-0.80
est: -0.72 (-11.1%)
|
-0.52
est: -0.69 (+24.7%)
|
-0.45
est: -0.21 (-114.3%)
|
-0.37
-0.37 – -0.37
-76.2% YoY
|
-0.27
-0.27 – -0.27
+27.0% YoY
|
0.08
0.08 – 0.08
+129.6% YoY
|
0.50
0.50 – 0.50
+525.0% YoY
|
0.80
0.80 – 0.80
+60.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edvard Hall | Chief Executive Officer? | — | male |
| Klas Ingstorp | Chief Operating Officer | — | male |
| Kristofer Svensson | Chief Financial Officer | — | male |
| Mohammad H. A. Ibrahim | Founder & Advisor | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOEX.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
